InMed Pharmaceuticals regains Nasdaq compliance on $1 minimum bid price rule

InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc.

INM

0.00
  • InMed Pharmaceuticals regained compliance with Nasdaq’s $1 minimum bid price rule, removing a continued-listing risk for its shares.
  • Nasdaq determined the stock closed at or above $1 for 10 consecutive business days from May 19 to June 2.
  • The company had received a Nasdaq notice on March 27 for failing to meet the $1 threshold for 30 straight business days.
  • Nasdaq closed the matter on June 3.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062993-26-003132), on June 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.